U.S. Cancer Vaccines Market

Nearly nine million people suffer from cancer in the United States, and more than one million new cases are expected every year. Revolutionary breakthroughs in cancer treatment research, in the form of specialized vaccines, are bringing new hope in the fight against the second-largest disease in America. Vaccines for melanoma and colorectal cancer are expected to enter the marketplace as early as 2002,and there are more than 150 other therapies in various stages of research and development. As these vaccines become FDA approved, market revenues will experience tremendous growth. This compelling Frost &Sullivan research analyzes the U.S. cancer vaccines market, including first-to-market products and the latest developments related to melanoma, prostate, colorectal, breast, lung, and other types of can- cer.It also identifies the strategies to take advantage of lucrative market opportunities.

Decisions Made Now Determine Future Success

"Most biotechnology companies are forming alliances with large pharmaceutical houses for the marketing and distribution of their products in order to maximize their chances of success," states the author of this research. Increased market shares will go to participants that are the first to penetrate the industry when their therapies receive FDA approval. These companies will already have sales, marketing, and distribution channels in place or through partnerships with another companies.

Educational Campaigns Increase Product Acceptance and Sales

The medical community is eagerly awaiting the introduction of cancer vaccines, and is receptive to innovative treatments that have solid clinical and statistical data and FDA approval.

"Companies should concentrate on educating physicians on the advantages, disadvantages, and usage of cancer vaccines," states the author. "Physicians will expect a great deal from cancer vaccines, and as with any new class of drugs, building the confidence of doctors for cancer vaccine treatment can take some time."

On-going vaccine clinical trials clearly show benefits over existing therapies. These drugs can add to the efficacy of existing therapies and improve the patient 's quality of life. This in-depth research gives users an edge over less- informed competition in the emerging U.S. cancer vaccines markets.